Determination of the optimal pool size of ABO-matched buffy coat (BC) units to achieve a typical adult dose (TAD) of platelets comparable to single donor platelet concentrate (SDPC): A single-center study
Abstract
BACKGROUND: The study aimed to determine the optimal pool size of ABO matched buffy coat pooled platelets (BCPP) to achieve a typical adult dose (TAD) of platelets comparable to single donor platelet concentrates (SDPC), following recent regulatory changes allowing random donor platelet concentrate (and/or buffy coat [BC]) pooling, in India. MATERIALS AND METHODS: This prospective study, done in 2024 at a tertiary hospital, included donors who met whole blood (WB) or SDPC donation criteria. WB was collected in quadruple bags and separated into red cells, plasma, and BC. BC units were pooled into groups of 4, 5, or 6 with 300 mL of ABO-matched plasma. SDPC was collected with automatic separators. The study examined four groups: BCPP, prepared from pools of four, five, or six BC units, and SDPC; 10 pools of BCPP (from three pool sizes of BC), and 10 units (SDPC) were assessed for in vitro parameters. Subsequently, conducted pilot in vivo study looked at the corrected count increment (CCI) and percentage platelet recovery (PPR) of the “optimal pool,” identified on the basis of in vitro analysis. RESULTS: The study used 150 WB and 10 SDPC donors, having no significant variations in physical, biochemical, or hematological markers across four groups. Pool-of-5 BC units met TAD standards with fewer units than pool-of-6 and produced comparable quality to SDPC. Transfusion of BCPP (pool-of-5) resulted in a CCI of 9.7 ± 4 × 10⁹/L and a PPR of 25 ± 11%. CONCLUSION: BCPP (pool-of-five BC units) provides an effective TAD, making it viable option to SDPC, with comparable quality and effectiveness.
Related
- PO021 | PLATELETS MATTER: THROMBIN GENERATION IN PLATELET‐RICH PLASMA VERSUS PLATELET-POOR-PLASMA UNDER NON-REPLACEMENT THERAPIES IN HAEMOPHILIA
- Intravesical Allogeneic Platelet Concentrate for Refractory BK Virus-Associated Haemorrhagic Cystitis After Allogeneic Haematopoietic Stem Cell Transplantation.
- Platelets in sickle cell disease: biomarkers, mediators, and lessons from clinical trials
- Efficacy and safety of bone marrow aspirate and bone marrow aspirate concentrate in orthopedic conditions: a systematic review of randomized controlled trials
- Bone Marrow Aspirate Concentrate Combined With Demineralized Bone Matrix With Open Curettage vs Mini-Open Trocar-Assisted Injection for Unicameral Bone Cysts: A Retrospective Comparative Study
BibTeX
@article{tiwari2026determination,
title = {{Determination of the optimal pool size of ABO-matched buffy coat (BC) units to achieve a typical adult dose (TAD) of platelets comparable to single donor platelet concentrate (SDPC): A single-center study}},
author = {Aseem Kumar Tiwari and Geet Aggarwal and Gautam Gupta and Gunjan Bhardwaj and Jyoti Sharma and Rajesh Deshpande},
journal = {Asian Journal of Transfusion Science},
year = {2026},
month = jul,
doi = {10.4103/ajts.ajts_26_25},
url = {https://doi.org/10.4103/ajts.ajts_26_25},
note = {CC BY-NC-SA},
}
RIS
TY - JOUR
TI - Determination of the optimal pool size of ABO-matched buffy coat (BC) units to achieve a typical adult dose (TAD) of platelets comparable to single donor platelet concentrate (SDPC): A single-center study
AU - Aseem Kumar Tiwari
AU - Geet Aggarwal
AU - Gautam Gupta
AU - Gunjan Bhardwaj
AU - Jyoti Sharma
AU - Rajesh Deshpande
PY - 2026
DA - 2026/07/01
JO - Asian Journal of Transfusion Science
DO - 10.4103/ajts.ajts_26_25
UR - https://doi.org/10.4103/ajts.ajts_26_25
AB - BACKGROUND: The study aimed to determine the optimal pool size of ABO matched buffy coat pooled platelets (BCPP) to achieve a typical adult dose (TAD) of platelets comparable to single donor platelet concentrates (SDPC), following recent regulatory changes allowing random donor platelet concentrate (and/or buffy coat [BC]) pooling, in India. MATERIALS AND METHODS: This prospective study, done in 2024 at a tertiary hospital, included donors who met whole blood (WB) or SDPC donation criteria. WB was collected in quadruple bags and separated into red cells, plasma, and BC. BC units were pooled into groups of 4, 5, or 6 with 300 mL of ABO-matched plasma. SDPC was collected with automatic separators. The study examined four groups: BCPP, prepared from pools of four, five, or six BC units, and SDPC; 10 pools of BCPP (from three pool sizes of BC), and 10 units (SDPC) were assessed for in vitro parameters. Subsequently, conducted pilot in vivo study looked at the corrected count increment (CCI) and percentage platelet recovery (PPR) of the “optimal pool,” identified on the basis of in vitro analysis. RESULTS: The study used 150 WB and 10 SDPC donors, having no significant variations in physical, biochemical, or hematological markers across four groups. Pool-of-5 BC units met TAD standards with fewer units than pool-of-6 and produced comparable quality to SDPC. Transfusion of BCPP (pool-of-5) resulted in a CCI of 9.7 ± 4 × 10⁹/L and a PPR of 25 ± 11%. CONCLUSION: BCPP (pool-of-five BC units) provides an effective TAD, making it viable option to SDPC, with comparable quality and effectiveness.
SN - 0973-6247
SN - 1998-3565
ER -